title: [Antiplatelet drugs and gastrointestinal disorders: when and how effective are inhibitors of proton pump?].
abstract: Antiplatelet drugs are essential in current treatment of coronary heart disease (CHD) but they have an adverse action--damage to gastrointestinal mucosa. Long-term administration of several medicines in CHD patients makes possible interaction of some drugs. Clinical trials show that proton pump inhibitors (PPI) reduce frequency of recurrent gastrointestinal bleedings in patients of high cardiological risk on antiplatelet therapy. In prescription of PPI to CHD patients at high risk of gastropathy, it is necessary to consider both efficacy and safety of the drug.
mesh_terms: D003327:Coronary Disease / Q000097:blood / Q000150:complications / Q000188:drug therapy; D006471:Gastrointestinal Hemorrhage / Q000097:blood / Q000139:chemically induced*; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use*; D054328:Proton Pump Inhibitors / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use*
chemical_list: D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors